Psycho-demographic profile in severe asthma and effect of emotional mood disorders and hyperventilation syndrome on quality of life

Abstract

Background Severe asthma affects a small population but carries a high psychopathological risk. Therefore, the psychodemographic profile of these patients is of interest. A substantial prevalence of anxiety, depression, alexithymia and hyperventilation syndrome in severe asthma is known, but contradictory results have been observed. These factors can also affect patients’ quality of life. For this reasons, our purpose is to evaluate the psychodemographic profile of patients with severe asthma and assess the prevalence of anxiety, depression, alexithymia and hyperventilation syndrome and their impact on the quality of life of patients with severe asthma. Methods A cross-sectional study of 63 patients with severe asthma. Their psychodemographic profile was evaluated using the Hospital Anxiety and Depression Scale (HADS), Toronto Alexithymia Scale (TAS-20), Nijmegen questionnaire and Asthma Control Test (ACT) to determine the state of anxiety and depression, alexithymia, hyperventilation syndrome and control of asthma, respectively. Quality of life was assessed with the Mini Asthma Quality of Life Questionnaire (Mini-AQLQ). Results The mean age was 60 ± 13.6 years. Personal psychopathological histories were found in 65.1% of participants, and 8% reported previous suicidal attempts. The rate of anxiety and/or depression (HADS ≥ 11) was 68.3%. These patients present higher scores on the TAS-20 (p < 0.001) for the level of dyspnea (p = 0.021), and for emotional function (p = 0.017) on the Mini-AQLQ, compared with patients without anxiety or depression. Alexithymia (TAS-20 ≥ 61) was observed in 42.9% of patients; these patients were older (p = 0.037) and had a higher HADS score (p = 0.019) than patients with asthma without alexithymia. On the other hand, patients with hyperventilation syndrome (Nijmegen ≥ 23) scored higher on the HADS (p < 0.05), on the Mini-AQLQ (p = 0.002) and on the TAS-20 (p = 0.044) than the group without hyperventilation syndrome. Quality of life was related to anxiety-depression symptomatology (r = − 0.302; p = 0.016) and alexithymia (r = − 0.264; p = 0.036). Finally, the Mini-AQLQ total score was associated with the Nijmegen questionnaire total score (r = − 0.317; p = 0.011), and the activity limitation domain of the Mini-AQLQ correlated with the ACT total score (r = 0.288; p = 0.022). Conclusions The rate of anxiety, depression, alexithymia and hyperventilation syndrome is high in patients with severe asthma. Each of these factors is associated with a poor quality of life.

Prevalence of and factors associated with alexithymia among patients with chronic obstructive pulmonary disease in China: a cross-sectional study

“…Consistent with previous research findings, our results showed that alexithymia was highly correlated with the degree of anxiety and depression in patients with COPD [ 15 , 36 , 37 ]. Anxiety and depression in patients with COPD not only aggravate the disease burden but also more likely lead to early death [ 38 ].…”

“…Second, patients with COPD tended to have more symptoms of alexithymia when SGRQ score was high. Alexithymia negatively impacts the health-related quality of life of the patients, regardless of the instrument used to define quality of life [ 41 , 42 ] and in particular, patients with severe asthma [ 37 , 43 ]. Even after the timely resolution of depression, alexithymia still reduces the quality of life of patients with obstructive sleep apnea [ 13 ].…”

Investigation of the incidence of immunisation stress-related response following COVID-19 vaccination in healthcare workers

“…In contrast, the relationship between a history of allergy and the incidence of ISRR has not been investigated. Patients with asthma, among the most common allergy-related diseases, are also known to experience high levels of anxiety and depression [ 31 , 32 ]. Considering that anxiety is a risk factor for ISRR, patients with a history of allergy should be strategically addressed.…”

The role of immunomodulatory preparations in asthma treatment

“…[4] The manifestations affect patients' quality of life by sleep disturbance and lead to an increased rate of anxiety, depression, and alexithymia among patients. [5] Described manifestations and a significant impact on patients' life, make it necessary to conduct effective treatment. Guidelines classify asthma treatment into 4 or 5 steps by the severity of symptoms and extent of disease control.…”